Demant CEO: Prognosis held back by uncertainty about momentum's duration

Demant’s first-quarter success was partially due to the launch of flagship product Oticon Real, which created particular interest among hearing aid users.
Søren Nielsen, chief executive officer of Demant. | Photo: Kenneth Lysbjerg Koustrup
Søren Nielsen, chief executive officer of Demant. | Photo: Kenneth Lysbjerg Koustrup
by marketwire, translated by christian radich hoffman

Hearing aid manufacturer Demant’s upwards adjustment of its 2023 prognosis in mid-April is mainly steered by the strong development during the year’s first quarter.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading